LAKEFRONT BIOTHERAPEUTICS NV (LKFT) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of LAKEFRONT BIOTHERAPEUTICS NV stock €88.86, price €29.62, upside +200.0%, quality 71 out of 100. Rating: strongly undervalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
Show moreShow less
The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Stock analysis
LAKEFRONT BIOTHERAPEUTICS NV (LKFT) currently trades at €29.62, while our model-based Fair Value estimate is €88.86, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €226.24 per share, and 15 of the 15 models we run sit above the €29.62 price.
Bear case: the Asset-Based group reads lowest at €44.14, and 0 of the 15 models stay below the price. Data coverage for this calculation is low.
Scenario range: €49.67 (bear) to €115.05 (bull), the price of €29.62 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
LAKEFRONT BIOTHERAPEUTICS NV reported revenue of €1.1B in FY2025 versus €485M in FY2021, a compound +23.1%/yr. Reported net income was €321M in FY2025.
Key figures
Market cap €1.9B Mid · P/E ratio 3.3 · P/S ratio 1.96 · EPS (TTM) €8.99 · Net margin 60.2% · Return on equity 20.1% · Return on assets (EBIT) 0.4% (5-year average) · Operating margin −359%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 75 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 200%, LKFT screens cheaper than that median.
Fair Value models
Bear€49.67Fair Value €88.86Bull€115.05
Price €29.62 · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€7.68 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+303.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+66.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.4%
Start year 2020 (pandemic). Over 10 years: +39.6% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+19.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+19.8%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.16.1% vs 16.0%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−37% → 45%
Compare LAKEFRONT BIOTHERAPEUTICS NV with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 9/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score71 · Top 25%
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (12 months)20.1% · Top 25%
Return on assets9.4% · Top 25%
Net margin (12 months)60.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−81.5% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is LAKEFRONT BIOTHERAPEUTICS NV (LKFT) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of €88.86 versus a price of €29.62, about +200% upside (undervalued).
What is the fair value of LKFT?
Our model-based fair value for LAKEFRONT BIOTHERAPEUTICS NV is €88.86 (as of Nov 6, 2026), built from audited fundamentals. The current price: €29.62.
What is the quality score of LKFT?
LAKEFRONT BIOTHERAPEUTICS NV has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LAKEFRONT BIOTHERAPEUTICS NV (LKFT)?
Our model-based price target is the fair value of €88.86 (as of Nov 6, 2026) from 15 valuation models. Cautious scenario €49.67, optimistic scenario €115.05. It is a calculation from audited fundamentals, not an analyst target.
What is the LAKEFRONT BIOTHERAPEUTICS NV stock forecast for 2026?
Our models put fair value at €88.86, about +200% upside versus a price of €29.62 (undervalued). Cautious scenario €49.67, optimistic scenario €115.05. The calculation is refreshed regularly with new filings.
What is the revenue of LAKEFRONT BIOTHERAPEUTICS NV (LKFT)?
LAKEFRONT BIOTHERAPEUTICS NV reported trailing-twelve-month revenue of about €991M (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of LAKEFRONT BIOTHERAPEUTICS NV (LKFT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LAKEFRONT BIOTHERAPEUTICS NV it is €88.86 per share (as of Nov 6, 2026), against a price of €29.62. It is the blended result of 15 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is LAKEFRONT BIOTHERAPEUTICS NV stock overvalued or undervalued in 2026?
As of Nov 6, 2026, LKFT trades below its calculated fair value: price €29.62, fair value €88.86, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LKFT?
No. The price is what the market pays today (€29.62); the fair value is what the company's own numbers justify (€88.86). For LAKEFRONT BIOTHERAPEUTICS NV the two are €59.24 per share apart. That gap is exactly why we show both numbers side by side.
How much is LAKEFRONT BIOTHERAPEUTICS NV worth?
The market values LAKEFRONT BIOTHERAPEUTICS NV at about €1.9B (market capitalisation, as of Nov 6, 2026). Per share that is €29.62; our models calculate a fair value of €88.86 per share.
What do the bullish and bearish scenarios say about LKFT?
Our models span a range for LAKEFRONT BIOTHERAPEUTICS NV: cautious scenario €49.67, base €88.86, optimistic €115.05 per share (as of Nov 6, 2026, price €29.62). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LKFT?
LAKEFRONT BIOTHERAPEUTICS NV trades at a price-to-earnings ratio of 3.3 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €88.86 is built from several models across several years. Other multiples: P/B 0.6, P/S 2.0, EV/EBITDA 3.3.
How solid is the balance sheet of LAKEFRONT BIOTHERAPEUTICS NV (LKFT)?
Balance-sheet figures for LAKEFRONT BIOTHERAPEUTICS NV (as of Nov 6, 2026): return on equity 20.1%. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
Which stocks are comparable to LAKEFRONT BIOTHERAPEUTICS NV?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LAKEFRONT BIOTHERAPEUTICS NV stock attractive at the current price?
The data as of Nov 6, 2026: price €29.62, calculated fair value €88.86 (+200%), Quality Score 71/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LKFT calculated?
We run LAKEFRONT BIOTHERAPEUTICS NV through 15 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €88.86 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. LAKEFRONT BIOTHERAPEUTICS NV currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LAKEFRONT BIOTHERAPEUTICS NV (LKFT)?
The closing price on Nov 6, 2026 was €29.62. Our model-based fair value is €88.86, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LAKEFRONT BIOTHERAPEUTICS NV right now?
The price is below even our cautious bear case (€49.67). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (71/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (€49.67 to €115.05) leaves room in how you read the outcome.
Key figures of LAKEFRONT BIOTHERAPEUTICS NV
How large is the market capitalisation of LAKEFRONT BIOTHERAPEUTICS NV (LKFT)?
The market capitalisation of LAKEFRONT BIOTHERAPEUTICS NV is €1.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LAKEFRONT BIOTHERAPEUTICS NV (LKFT)?
The price-to-sales ratio of LAKEFRONT BIOTHERAPEUTICS NV is 1.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of LAKEFRONT BIOTHERAPEUTICS NV (LKFT)?
Earnings per share at LAKEFRONT BIOTHERAPEUTICS NV are €8.99 (price ÷ EPS = P/E 3.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of LAKEFRONT BIOTHERAPEUTICS NV (LKFT)?
The net margin of LAKEFRONT BIOTHERAPEUTICS NV is 60.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of LAKEFRONT BIOTHERAPEUTICS NV (LKFT)?
The return on equity (ROE) of LAKEFRONT BIOTHERAPEUTICS NV is 20.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LAKEFRONT BIOTHERAPEUTICS NV (LKFT)?
On an EBIT basis the return on assets of LAKEFRONT BIOTHERAPEUTICS NV is 0.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LAKEFRONT BIOTHERAPEUTICS NV (LKFT)?
The operating margin of LAKEFRONT BIOTHERAPEUTICS NV is −359% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LAKEFRONT BIOTHERAPEUTICS NV (LKFT)?
Revenue at LAKEFRONT BIOTHERAPEUTICS NV is growing −81.5% versus a year earlier (3y avg +66.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does LAKEFRONT BIOTHERAPEUTICS NV (LKFT) generate?
The free cash flow of LAKEFRONT BIOTHERAPEUTICS NV is −€211M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does LAKEFRONT BIOTHERAPEUTICS NV (LKFT) hold?
LAKEFRONT BIOTHERAPEUTICS NV holds more cash than debt, €81.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch LAKEFRONT BIOTHERAPEUTICS NV in the live analysis
One click puts LAKEFRONT BIOTHERAPEUTICS NV on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026